Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Zarnestra (tipifarnib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Kura Oncology

Drug class:

CXCL12 inhibitor, Farnesyl transferase inhibitor

Related drugs:

‹

›

HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
HRAS mutation	Urothelial Cancer	HRAS mutation	Urothelial Cancer	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2	tipifarnib Sensitive: C2 – Inclusion Criteria tipifarnib Sensitive : C2
HRAS G13R	Urothelial Cancer	HRAS G13R	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS Q61R	Urothelial Cancer	HRAS Q61R	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS G12S	Urothelial Cancer	HRAS G12S	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS G12C	Urothelial Cancer	HRAS G12C	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS H27_28fs*	Urothelial Cancer	HRAS H27_28fs*	Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
CXCL12 overexpression	T Cell Non-Hodgkin Lymphoma	CXCL12 overexpression	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
KIR3DL2 Q386E	T Cell Non-Hodgkin Lymphoma	KIR3DL2 Q386E	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
KIR3DL2 C336R	T Cell Non-Hodgkin Lymphoma	KIR3DL2 C336R	T Cell Non-Hodgkin Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
HRAS mutation	Salivary Gland Cancer	HRAS mutation	Salivary Gland Cancer	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3
CXCL12 expression	Peripheral T-cell Lymphoma	CXCL12 expression	Peripheral T-cell Lymphoma	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3	tipifarnib Sensitive: C3 – Early Trials tipifarnib Sensitive : C3